Actively Recruiting
A Clinical Study of MK-8294 in Participants With Advanced Solid Tumors (MK-8294-001)
Led by Merck Sharp & Dohme LLC · Updated on 2026-03-16
67
Participants Needed
5
Research Sites
108 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
MK-8294, the study medicine, is a type of targeted therapy designed to treat certain solid tumors. The main goals of this study are to learn about the safety of MK-8294 and if people can tolerate it and find the highest dose level of MK-8294 that people can tolerate.
CONDITIONS
Official Title
A Clinical Study of MK-8294 in Participants With Advanced Solid Tumors (MK-8294-001)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Has histologically or cytologically confirmed advanced/metastatic solid tumor including specific cancers such as head and neck, cervical, esophageal, breast, endometrial, and bladder cancer
- Previously failed standard treatment, lacks standard treatment options, or is intolerant to standard treatment
- HIV-infected participants must have well-controlled HIV on antiretroviral therapy
- Hepatitis B surface antigen positive participants must have received antiviral therapy for at least 4 weeks and have undetectable viral load
- Participants with history of hepatitis C virus infection are eligible if viral load is undetectable
You will not qualify if you...
- HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
- History of New York Heart Association Class II or greater heart failure
- Prior immunotherapy discontinued due to Grade 3 or higher immune-related adverse events (except certain endocrine disorders) or Grade 2 myocarditis or recurrent Grade 2 pneumonitis
- Ongoing radiation-related toxicities requiring corticosteroids
- Known additional malignancy progressing or treated within the past 2 years
- Active central nervous system metastases and/or carcinomatous meningitis
- Active autoimmune disease requiring systemic treatment in the past 2 years except replacement therapy
- Active infection requiring systemic therapy
- History of stem cell or solid organ transplant
- Not adequately recovered from major surgery or has ongoing surgical complications
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 5 locations
1
Northwestern University ( Site 0101)
Chicago, Illinois, United States, 60611
Actively Recruiting
2
Rambam Health Care Campus ( Site 0201)
Haifa, Israel, 3109601
Actively Recruiting
3
Sheba Medical Center ( Site 0200)
Ramat Gan, Israel, 5265601
Actively Recruiting
4
Radboudumc ( Site 0301)
Nijmegen, Gelderland, Netherlands, 6525 GA
Actively Recruiting
5
Nederlands Kanker Instituut - Antoni van Leeuwenhoek - NKI-AVL ( Site 0300)
Amsterdam, North Holland, Netherlands, 1066 CX
Actively Recruiting
Research Team
T
Toll Free Number
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here